VERAXA Biotech AG and Voyager Acquisition Corp. Announce $1.64 Billion Merger to Advance Cancer Therapies
VERAXA Biotech AG and Voyager Acquisition Corp. have agreed to a $1.64 billion merger, aiming to accelerate the development of innovative cancer therapies through VERAXA's Bi-Targeted Antibody Cytotoxicity platform.
